{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:16:15Z","timestamp":1758046575394,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.pharma.2013.01.004","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:47:50Z","timestamp":1362772070000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Actualit\u00e9s th\u00e9rapeutiques\u00a0: l\u2019abirat\u00e9rone, le b\u00e9latacept, le vand\u00e9tanib et la fidaxomycine"],"prefix":"10.1016","volume":"71","author":[{"given":"C.","family":"Monneret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pharma.2013.01.004_bib0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5114\/aoms.2012.31610","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis","volume":"8","author":"Kawalec","year":"2012","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pharma.2013.01.004_bib0010","doi-asserted-by":"crossref","unstructured":"Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German Compassionate-use Programme. Eur Urol 2012, http:\/\/dx.doi.org\/10.1016\/j.eururo.2012.08.058, pii: S0302-2838(12)01011-1.","DOI":"10.1016\/j.eururo.2012.08.058"},{"key":"10.1016\/j.pharma.2013.01.004_bib0015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/CIA.S27930","article-title":"Management of bone metastases in refractory prostate cancer\u2013role of denosumab","volume":"7","author":"Paller","year":"2012","journal-title":"Clin Interv Aging"},{"issue":"10","key":"10.1016\/j.pharma.2013.01.004_bib0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301\u00a0randomised, double-blind, placebo-controlled phase 3\u00a0study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"Suppl.\u00a010","key":"10.1016\/j.pharma.2013.01.004_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/annonc\/mds353","article-title":"Novel and bone-targeted agents for CRPC","volume":"23","author":"Fizazi","year":"2012","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.pharma.2013.01.004_bib0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2013.01.004_bib0035","doi-asserted-by":"crossref","unstructured":"Croke J, Leung E, Segal R, Malone S. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review. BMJ Case Rep 2012, http:\/\/dx.doi.org\/10.1136\/bcr-2012-006540, pii: bcr2012006540.","DOI":"10.1136\/bcr-2012-006540"},{"issue":"4","key":"10.1016\/j.pharma.2013.01.004_bib0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1051\/medsci\/2006224354","article-title":"Une nouvelle mol\u00e9cule originale, immunosuppressive, en transplantation d\u2019organe M\/S","volume":"22","author":"Beaudreuil","year":"2006","journal-title":"Med Sci (Paris)"},{"issue":"3","key":"10.1016\/j.pharma.2013.01.004_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.pharma.2013.01.004_bib0050","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT EXT-STUDY)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.pharma.2013.01.004_bib0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.pharma.2013.01.004_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/EJE-08-0624","article-title":"Thyroid cancer: is the incidence rise abating?","volume":"160","author":"Sassolas","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharma.2013.01.004_bib0065","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1089\/thy.2009.1603","article-title":"Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances","volume":"19","author":"Schlumberger","year":"2009","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.pharma.2013.01.004_bib0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.pharma.2013.01.004_bib0075","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2\u00a0trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharma.2013.01.004_bib0080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2013.01.004_bib0085","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharma.2013.01.004_bib0090","unstructured":"http:\/\/www.institut-oncologie-thoracique.com\/archives\/niveau_de_mutation\/fusion-kif5b-ret. Consult\u00e9 le 11\u00a0d\u00e9cembre 2012."},{"issue":"35","key":"10.1016\/j.pharma.2013.01.004_bib0095","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1200\/JCO.2012.45.8240","article-title":"RET fusion genes in non-small-cell lung cancer","volume":"30","author":"Chao","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.pharma.2013.01.004_bib0100","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pharma.2013.01.004_bib0105","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450913000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450913000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:30:58Z","timestamp":1757719858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450913000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0003450913000242"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2013.01.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s th\u00e9rapeutiques\u00a0: l\u2019abirat\u00e9rone, le b\u00e9latacept, le vand\u00e9tanib et la fidaxomycine","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2013.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}